News

Immutep Appoints LAG-3 Pioneer, Frédéric Triebel to Board

SYDNEY, AUSTRALIA, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology…

2 years ago

Enlivex to Present at Upcoming Investor and Media Conferences

Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

2 years ago

Simply Better Brands Corp. Invited to Present at the Emerging Growth Conference on September 14, 2022

VANCOUVER, British Columbia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. ("SBBC" or the "Company") (TSX Venture: SBBC)…

2 years ago

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results

Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista® Remains on Track for MyoVista® FDA De…

2 years ago

Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections

Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of…

2 years ago

Locus Biosciences Announces First Patient Treated in the ELIMINATE Registrational Phase 2/3 Trial of LBP-EC01 for Urinary Tract Infections

Marks first randomized Phase 2/3 trial of CRISPR-enhanced bacteriophage precision medicineRESEARCH TRIANGLE PARK, N.C., Sept. 13, 2022 (GLOBE NEWSWIRE) --…

2 years ago

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02

FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD…

2 years ago

Salarius Pharmaceuticals CEO Issues Letter to Stockholders

HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients…

2 years ago

aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation for systemic sclerosis (SSc). SAN…

2 years ago

Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II

Las Vegas, NV, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a…

2 years ago